Palogic Value Management L.P. boosted its stake in Dolby Laboratories (NYSE:DLB – Free Report) by 6.3% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 4,132 shares of the electronics maker’s stock after acquiring an additional 244 shares during the period. Palogic Value Management L.P.’s holdings in Dolby Laboratories were worth $332,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Raymond James Financial Inc. purchased a new stake in shares of Dolby Laboratories in the fourth quarter valued at about $1,872,000. Hsbc Holdings PLC raised its holdings in shares of Dolby Laboratories by 692.7% in the fourth quarter. Hsbc Holdings PLC now owns 21,863 shares of the electronics maker’s stock valued at $1,713,000 after buying an additional 19,105 shares during the last quarter. Integrated Wealth Concepts LLC raised its holdings in shares of Dolby Laboratories by 10.7% in the fourth quarter. Integrated Wealth Concepts LLC now owns 3,448 shares of the electronics maker’s stock valued at $269,000 after buying an additional 334 shares during the last quarter. Voya Investment Management LLC raised its holdings in shares of Dolby Laboratories by 157.3% in the fourth quarter. Voya Investment Management LLC now owns 20,539 shares of the electronics maker’s stock valued at $1,604,000 after buying an additional 12,558 shares during the last quarter. Finally, Northern Trust Corp raised its holdings in shares of Dolby Laboratories by 5.6% in the fourth quarter. Northern Trust Corp now owns 582,004 shares of the electronics maker’s stock valued at $45,455,000 after buying an additional 30,826 shares during the last quarter. 58.56% of the stock is owned by hedge funds and other institutional investors.
Dolby Laboratories Stock Down 0.6%
NYSE DLB opened at $71.68 on Friday. The stock has a market capitalization of $6.87 billion, a P/E ratio of 26.26 and a beta of 0.91. Dolby Laboratories has a 52-week low of $68.24 and a 52-week high of $89.66. The firm has a 50-day moving average price of $74.24 and a 200 day moving average price of $76.27.
Dolby Laboratories Dividend Announcement
The company also recently declared a quarterly dividend, which was paid on Wednesday, August 20th. Investors of record on Tuesday, August 12th were issued a dividend of $0.33 per share. This represents a $1.32 annualized dividend and a yield of 1.8%. The ex-dividend date of this dividend was Tuesday, August 12th. Dolby Laboratories’s dividend payout ratio is currently 48.35%.
Insider Buying and Selling
In other Dolby Laboratories news, SVP Shriram Revankar sold 7,000 shares of the company’s stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $74.92, for a total transaction of $524,440.00. Following the transaction, the senior vice president directly owned 70,435 shares in the company, valued at approximately $5,276,990.20. This represents a 9.04% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Kevin J. Yeaman sold 39,875 shares of the company’s stock in a transaction dated Tuesday, July 15th. The stock was sold at an average price of $74.82, for a total transaction of $2,983,447.50. Following the transaction, the chief executive officer owned 114,725 shares in the company, valued at $8,583,724.50. The trade was a 25.79% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 148,049 shares of company stock valued at $11,045,581 over the last ninety days. Corporate insiders own 38.39% of the company’s stock.
Analysts Set New Price Targets
A number of brokerages have recently commented on DLB. Rosenblatt Securities reaffirmed a “buy” rating and issued a $95.00 target price on shares of Dolby Laboratories in a report on Friday, August 1st. Barrington Research reaffirmed an “outperform” rating and issued a $100.00 target price on shares of Dolby Laboratories in a report on Friday, May 2nd. Wall Street Zen raised shares of Dolby Laboratories from a “hold” rating to a “buy” rating in a report on Saturday. Finally, Tigress Financial upped their target price on shares of Dolby Laboratories from $112.00 to $114.00 and gave the company a “buy” rating in a report on Friday, August 15th. Three analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $103.00.
Get Our Latest Analysis on Dolby Laboratories
Dolby Laboratories Profile
Dolby Laboratories, Inc creates audio and imaging technologies that transform entertainment at the cinema, DTV transmissions and devices, mobile devices, OTT video and music services, home entertainment devices, and automobiles. The company develops and licenses its audio technologies, such as AAC & HE-AAC, a digital audio codec solution used for a range of media applications; AVC, a digital video codec with high bandwidth efficiency used in various media devices; Dolby AC-4, a digital audio coding technology that delivers new audio experiences to a range of playback devices; and Dolby Atmos technology for cinema and various media devices.
See Also
- Five stocks we like better than Dolby Laboratories
- What Are Dividends? Buy the Best Dividend Stocks
- Improving Fundamentals Drive New Buybacks for 3 Strong Performers
- EV Stocks and How to Profit from Them
- 3 Reasons Gartner Could Be the Best Buy of Q3
- How to Use the MarketBeat Dividend Calculator
- Free Cash Flow Boom Keeps Microsoft Ahead of the Pack
Want to see what other hedge funds are holding DLB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dolby Laboratories (NYSE:DLB – Free Report).
Receive News & Ratings for Dolby Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dolby Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.